MABE1084
Anti-Topoisomerase I-DNA Covalent Complexes Antibody, clone 1.1A
clone 1.1A, from mouse
Szinonimák:
Topoisomerase I-DNA covalent complex, DNA topoisomerase 1-DNA covalent complex, Topo I-DNA covalent complex, TopoI cc, TopoIcc
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(4)
About This Item
UNSPSC kód:
12352203
eCl@ss:
32160702
NACRES:
NA.41
klón:
1.1A, monoclonal
application:
DB
ELISA
FACS
ICC
ELISA
FACS
ICC
faj reaktivitás:
human, mouse
technika/technikák:
ELISA: suitable
dot blot: suitable
flow cytometry: suitable
immunocytochemistry: suitable
dot blot: suitable
flow cytometry: suitable
immunocytochemistry: suitable
citations:
18
Javasolt termékek
biológiai forrás
mouse
Minőségi szint
antitest forma
purified antibody
antitest terméktípus
primary antibodies
klón
1.1A, monoclonal
faj reaktivitás
human, mouse
technika/technikák
ELISA: suitable
dot blot: suitable
flow cytometry: suitable
immunocytochemistry: suitable
izotípus
IgG2bκ
NCBI elérési szám
UniProt elérési szám
kiszállítva
wet ice
célzott transzláció utáni módosítás
unmodified
Géninformáció
human ... TOP1(7150)
Általános leírás
DNA topoisomerase 1 (EC 5.99.1.2; UniProt P11387; also known as DNA topoisomerase I, Topo I) is encoded by the TOP1 (also known as TOPI) gene (Gene ID 7150) in human. Topo I relaxes double strand DNA (dsDNA) torsional strain by nicking one strand of the dsDNA to allow rotation of the nicked 3′-hydroxy end around the unnicked strand, while the 5′-phosphoryl end of the nicked DNA forms a covalent phosphodiester bond with a tyrosine residue on Topo I. The nicked 3′-hydroxy end then attacks the DNA-enzyme phosphoester bond to religate the nicked DNA strand. One supercoil is removed during each round of Topo I-catalyzed nicking and resealing. Camptothecins are widely used for cancer treatment, these drugs intercalate into DNA at the topo I active site, inhibiting the religation step of the enzyme and shifting the equilibrium toward covalent topo I-DNA complexes rather than free topo I and DNA. Interaction of these drug-stabilized covalent topo I-DNA complexes with advancing replication forks or transcription complexes causse further DNA damage and eventual cell death.
Egyediség
Clone 1.1A specifically recognizes topoisomerase I (Topo I) in DNA covalent complexes, but not non-DNA complexed, free Topo I by detecting topo I active site Tyr723 phosphorylation (Patel, A.G., et al, (2016). 44(6):2816-2826).
Immunogén
Epitope: Topo I pTyr723.
KLH-conjugated linear peptide corresponding to human Topo I target site sequence with phosphorylated Tyr723.
Alkalmazás
Anti-Topoisomerase I-DNA Covalent Complexes Antibody, clone 1.1A is an antibody against Topoisomerase I-DNA Covalent Complexes for use in Immunocytochemistry, Flow Cytometry, Dot Blot, ELISA.
Flow Cytometry Analysis: 1.0 µg of this antibody from a representative lot detected topoisomerase I/DNA covalent complexes in Topotecan-treated HCT116 human colon cancer cells.
Immunocytochemistry Analysis: 10 µg/mL from a representative lot detected topoisomerase I/DNA covalent complexes in Topotecan-treated A549 human lung carcinoma cells (Courtesy of Dr. Scott H. Kaufmann, Mayo Clinic, Rochester, MN).
Flow Cytometry Analysis: 10 µg/mL from a representative lot detected topoisomerase I/DNA covalent complexes in Topotecan-treated HCT116 human colon cancer cells (Courtesy of Dr. Scott H. Kaufmann, Mayo Clinic, Rochester, MN).
Dot Blot Analysis: A representative lot detected the Topotecan-/TPT-stablized topoisomerase I/DNA covalent complexes, but not free topoisomerase I (non-DNA complexed) by slot blot using CsCl2 gradient-fractionated lysates from TPT-treated and untreated A549 cells (Patel, A.G., et al, (2016). 44(6):2816-2826).
Dot Blot Analysis: A representative lot detected a Topotecan (TPT) dose-dependent increase of TPT-stabilized topoisomerase I/DNA covalent complexes in lysates from TPT-treated A549 and HCT116 cells by slot blot (Patel, A.G., et al, (2016). 44(6):2816-2826).
Dot Blot Analysis: A representative lot detected stabilized topoisomerase I/DNA covalent complexes in lysates from A549 cells treated with Camptothecins (CPT, SN-38, TPT) or Indenoisoquinolines (NSC 314622, NSC 725776, NSC 743400), but not nucleoside analogues (cytarabine and gemcitabine) (Patel, A.G., et al, (2016). 44(6):2816-2826).
ELISA Analysis: A representative lot detected the immunogen peptide corresponding to topoisomerase I active site sequence with phosphorylated Tyr723, but not the peptide with non-phosphorylated Tyr273 by direct (non-sandwich) ELISA (Patel, A.G., et al, (2016). 44(6):2816-2826).
Immunocytochemistry Analysis: A representative lot detected a dose-dependent increase of non-nucleolar topoisomerase I/DNA covalent complex loci in Topotecan-/TPT-treated A549 cells, while the small number of loci in untreated cells were seen only in nucleoli (Patel, A.G., et al, (2016). 44(6):2816-2826).
Immunocytochemistry Analysis: A representative lot detected a temporally and spatially distinct nuclear loci formation of topoisomerase I/DNA covalent complexes from those of phospho-H2AX and Rad51 in Topotecan-/TPT-treated A549 cells (Patel, A.G., et al, (2016). 44(6):2816-2826).
Immunocytochemistry Analysis: 10 µg/mL from a representative lot detected topoisomerase I/DNA covalent complexes in Topotecan-treated A549 human lung carcinoma cells (Courtesy of Dr. Scott H. Kaufmann, Mayo Clinic, Rochester, MN).
Flow Cytometry Analysis: 10 µg/mL from a representative lot detected topoisomerase I/DNA covalent complexes in Topotecan-treated HCT116 human colon cancer cells (Courtesy of Dr. Scott H. Kaufmann, Mayo Clinic, Rochester, MN).
Dot Blot Analysis: A representative lot detected the Topotecan-/TPT-stablized topoisomerase I/DNA covalent complexes, but not free topoisomerase I (non-DNA complexed) by slot blot using CsCl2 gradient-fractionated lysates from TPT-treated and untreated A549 cells (Patel, A.G., et al, (2016). 44(6):2816-2826).
Dot Blot Analysis: A representative lot detected a Topotecan (TPT) dose-dependent increase of TPT-stabilized topoisomerase I/DNA covalent complexes in lysates from TPT-treated A549 and HCT116 cells by slot blot (Patel, A.G., et al, (2016). 44(6):2816-2826).
Dot Blot Analysis: A representative lot detected stabilized topoisomerase I/DNA covalent complexes in lysates from A549 cells treated with Camptothecins (CPT, SN-38, TPT) or Indenoisoquinolines (NSC 314622, NSC 725776, NSC 743400), but not nucleoside analogues (cytarabine and gemcitabine) (Patel, A.G., et al, (2016). 44(6):2816-2826).
ELISA Analysis: A representative lot detected the immunogen peptide corresponding to topoisomerase I active site sequence with phosphorylated Tyr723, but not the peptide with non-phosphorylated Tyr273 by direct (non-sandwich) ELISA (Patel, A.G., et al, (2016). 44(6):2816-2826).
Immunocytochemistry Analysis: A representative lot detected a dose-dependent increase of non-nucleolar topoisomerase I/DNA covalent complex loci in Topotecan-/TPT-treated A549 cells, while the small number of loci in untreated cells were seen only in nucleoli (Patel, A.G., et al, (2016). 44(6):2816-2826).
Immunocytochemistry Analysis: A representative lot detected a temporally and spatially distinct nuclear loci formation of topoisomerase I/DNA covalent complexes from those of phospho-H2AX and Rad51 in Topotecan-/TPT-treated A549 cells (Patel, A.G., et al, (2016). 44(6):2816-2826).
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology
Chromatin Biology
Minőség
Evaluated by Immunocytochemistry in Topotecan-treated A549 human lung carcinoma cells.
Immunocytochemistry Analysis: 10 µg/mL of this antibody detected topoisomerase I/DNA covalent complexes in Topotecan-treated A549 human lung carcinoma cells.
Immunocytochemistry Analysis: 10 µg/mL of this antibody detected topoisomerase I/DNA covalent complexes in Topotecan-treated A549 human lung carcinoma cells.
Cél megnevezése
90.7 kDa calculated.
Fizikai forma
Format: Purified
Protein G purified.
Purified mouse IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Tárolás és stabilitás
Stable for 1 year at 2-8°C from date of receipt.
Egyéb megjegyzések
Concentration: Please refer to lot specific datasheet.
Jogi nyilatkozat
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Nem találja a megfelelő terméket?
Próbálja ki a Termékválasztó eszköz. eszközt
Tárolási osztály kódja
12 - Non Combustible Liquids
WGK
WGK 1
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Analitikai tanúsítványok (COA)
Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
Shih-Chieh Chiang et al.
Science advances, 3(4), e1602506-e1602506 (2017-05-17)
Breakage of one strand of DNA is the most common form of DNA damage. Most damaged DNA termini require end-processing in preparation for ligation. The importance of this step is highlighted by the association of defects in the 3'-end processing
Naoto Shimizu et al.
The Journal of biological chemistry, 299(8), 104988-104988 (2023-07-02)
Topoisomerases are enzymes that relax DNA supercoiling during replication and transcription. Camptothecin, a topoisomerase 1 (TOP1) inhibitor, and its analogs trap TOP1 at the 3'-end of DNA as a DNA-bound intermediate, resulting in DNA damage that can kill cells. Drugs
Ignacio Torrecilla et al.
Nucleic acids research, 52(2), 525-547 (2023-12-12)
DNA-protein crosslinks (DPCs) are toxic DNA lesions wherein a protein is covalently attached to DNA. If not rapidly repaired, DPCs create obstacles that disturb DNA replication, transcription and DNA damage repair, ultimately leading to genome instability. The persistence of DPCs
Angela M Mabb et al.
PloS one, 11(5), e0156439-e0156439 (2016-05-28)
Topoisomerase 1 (TOP1) inhibitors, including camptothecin and topotecan, covalently trap TOP1 on DNA, creating cleavage complexes (cc's) that must be resolved before gene transcription and DNA replication can proceed. We previously found that topotecan reduces the expression of long (>100
Amy Flor et al.
Cell chemical biology, 28(6), 776-787 (2020-12-23)
Topoisomerase 1 (Top1) reversibly nicks chromosomal DNA to relax strain accumulated during transcription, replication, chromatin assembly, and chromosome condensation. The Top1 poison camptothecin targets cancer cells by trapping the enzyme in the covalent complex Top1cc, tethered to cleaved DNA by
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással